Prevention of severe RSV-associated lower respiratory tract infections in children at high risk of RSV infection: use of palivizumab
- Authors: Borzakova S.N.1,2,3, Mikheeva A.A.1,4, Esmurzieva Z.I.4
-
Affiliations:
- Research Institute for Healthcare Organization and Medical Management, Moscow Health Department
- Russian Medical Academy of Continuous Professional Education
- Children’s City Clinical Hospital named after Z.A. Bashlyaeva, Moscow Health Department
- Morozov Children’s City Clinical Hospital, Moscow Health Department
- Issue: Vol 32, No 9 (2025)
- Pages: 49-53
- Section: Pulmonology/ENT/ARVI
- URL: https://medbiosci.ru/2073-4034/article/view/368192
- DOI: https://doi.org/10.18565/pharmateca.2025.9.49-53
- ID: 368192
Cite item
Open Access
Access granted
Subscription Access
Abstract
Respiratory syncytial infection (RSVI) is one of the main causes of lower respiratory tract infections in children under 2 years of age. Children born before 35 weeks of gestation, children with bronchopulmonary dysplasia, hemodynamically significant heart defects, and immunodeficiency states are at risk for severe RSVI.
Currently, the most effective and safe method for preventing RSVI is immunization with palivizumab. Palivizumab contains monoclonal IgG1 antibodies against the F protein of the virus, which prevents the virus from attaching to respiratory epithelial cells and prevents severe RSVI. Five injections of palivizumab are required for effective immune protection.
Prophylaxis with palivizumab leads to a significant reduction in the incidence of RSVI after two years of follow-up and reduces the frequency and duration of episodes of bronchial obstruction during one year of follow-up.
About the authors
Svetlana N. Borzakova
Research Institute for Healthcare Organization and Medical Management, Moscow Health Department; Russian Medical Academy of Continuous Professional Education; Children’s City Clinical Hospital named after Z.A. Bashlyaeva, Moscow Health Department
Author for correspondence.
Email: pharmateca@yandex.ru
ORCID iD: 0000-0001-5544-204X
Scopus Author ID: 55883991400
Cand. Sci. (Med.), Research
Russian Federation, Moscow; Moscow; MoscowAnna A. Mikheeva
Research Institute for Healthcare Organization and Medical Management, Moscow Health Department;Morozov Children’s City Clinical Hospital, Moscow Health Department
Email: pharmateca@yandex.ru
ORCID iD: 0000-0001-9092-6453
Cand. Sci. (Med.)
Russian Federation, Moscow; MoscowZareta I. Esmurzieva
Morozov Children’s City Clinical Hospital, Moscow Health Department
Email: pharmateca@yandex.ru
ORCID iD: 0009-0004-4806-4545
Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Клинические рекомендации оказания медицинской помощи детям Министерства здравоохранения РФ «Респираторно-синцитиальная инфекция у детей», 2024. [Clinical guidelines for the provision of medical care to children of the Ministry of Health of the Russian Federation «Respiratory syncytial infection in children», 2024. (In Russ.)]. URL: https://cr.minzdrav.gov.ru/preview-cr/943_1 (дата обращения / date of access: 21.09.2025).
- Garegnani L., Styrmisdóttir L., Roson Rodriguez P., et al. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children Cochrane Database Syst Rev. 2021;11(11):CD013757. https://dx.doi.org/10.1002/14651858.CD013757.pub2
- Чубарова А.И., Давыдова И.В., Виноградова И.В. и др. Эффективность паливизумаба в снижении частоты госпитализации детей с РСВ инфекцией в группах высокого риска: проспективное наблюдательное многоцентровое исследование. Вестник РАМН. 2017;72 (4):282–289. [Chubarova A.I., Davydova I.V., Vinogradova I.V., et al. Efficacy of palivizumab in reducing the incidence of hospitalization in children with RSV infection in high-risk groups: a prospective observational multicenter study. Bulletin of the Russian Academy of Medical Sciences. 2017;72 (4):282–289. (In Russ.)]. https://dx.doi.org/10.15690/vramn855
- Suss R.J., Simões E.A.F. An evaluation of 2015–2019 United States respiratory syncytial virus hospitalizations as a framework to develop potential strategies for the preventiosn of the hospital burden among infants. eClinicalMedicine. 2024;75:102790. https://dx.doi.org/10.1016/j.eclinm.2024.102790
- Winthrop Z.A., Perez J.M., Staffa S.J., et al. Pediatric respiratory syncytial virus hospitalizations and respiratory support after the COVID-19 pandemic. JAMA Netw Open. 2024;7(6):e2416852. https://dx.doi.org/10.1001/jamanetworkopen.2024.16852
- Экспертный консенсус по вопросам иммунопрофилактики РСВ-инфекции среди детей групп риска от 27.10.2023. [Expert consensus on issues of immunization against RSV infection among children at risk, dated October 27, 2023. (In Russ.)]. URL: https://nnoi.ru/tpost/c6cozg1f51-ekspertnii-konsensus-po-voprosam-immunop (дата обращения / date of access: 21.09.2025).
- De Jesús-González L.A., León-Juárez M., Lira-Hernández F.I., et al. Advances and Challenges in Antiviral Development for Respiratory Viruses. Pathogens. 2024;14(1):20. https://dx.doi.org/10.3390/pathogens14010020
- Fleming-Dutra K.E., Jones J.M., Roper L.E., et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115–1122. https://dx.doi.org/10.15585/mmwr.mm7241e1
- Государственный реестр лекарственных средств. [State register of medicines. (In Russ.)]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7d92b576-1f8e-40ac-9cd4-f4ce90fdf457 (дата обращения / date of access: 05.10.2025).
- Ибрагимова Ю.Н., Вахлова И.В., Сафронова Л.Е., Кршеминская И.В. Влияние иммунопрофилактики респираторно-синцитиальной вирусной инфекции у детей групп риска тяжёлого течения и её завершенности на частоту повторных эпизодов бронхиальной обструкции, внебольничной пневмонии в раннем возрасте. Журнал инфектологии. 2025;17(3):106–112. [Ibragimova Yu.N., Vakhlova I.V., Safronova L.E., Krsheminskaya I.V. The influence of immunoprophylaxis of respiratory syncytial virus infection in children at risk of severe course and its completion on the frequency of repeated episodes of bronchial obstruction, community-acquired pneumonia in early age. Journal of Infectology. 2025;17(3):106-112. (In Russ.)]. https://dx.doi.org/10.22625/2072-6732-2025-17-3-106-112
- Распоряжение Департамента здравоохранения города Москвы от 25.12.2024 № 4491-р «О мероприятиях, направленных на внесезонную профилактику респираторно-синцитиальной вирусной инфекции у детей в городе Москве, за счёт средств бюджета города Москвы». [Moscow Department of Healthcare Order No. 4491-r dated December 25, 2024, «On measures aimed at off-season prevention of respiratory syncytial virus infection in children in Moscow, funded by the Moscow city budget». (In Russ.)].
- Информационное письмо Федерального государственного бюджетного учреждения «Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства» от 13.03.2023 № 01-21/307 «О рекомендуемых сроках иммунопрофилактики респираторно-синцитиальной инфекции у детей из групп риска». [Information letter of the Federal State Budgetary Institution «Children’s Scientific and Clinical Center for Infectious Diseases of the Federal Medical and Biological Agency» dated March 13, 2023, No. 01-21/307 «On the recommended timing of immunization against respiratory syncytial infection in children at risk». (In Russ.)]. URL: http://niidi.ru/dotAsset/1096e043-53cc-4ee7-a7c8-292374f1eede.pdf (дата обращения / date of access: 21.09.2025).
- Mac S., Sumner A., Duchesne-Belanger S., et al. Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review. Pediatrics. 2019;143(5):e20184064. https://dx.doi.org/10.1542/peds.2018-4064
- Овсянников Д.Ю., Зуев А.В., Аюшин Э.И. и др. Иммунопрофилактика респираторно-синцитиальной вирусной инфекции: почему, кому, когда, как? Вопросы практической педиатрии. 2024;19(4):85–96. [Ovsyannikov D.Yu., Zuev A.V., Ayushin E.I., et al. Immunoprophylaxis of respiratory syncytial virus infection: why, to whom, when, how? Issues of practical pediatrics. 2024;19(4):85–96. (In Russ.)]. https://dx.doi.org/10.20953/1817-7646-2024-4-85-96
Supplementary files
